Newstral
Article
CNN on 2020-04-24 09:28
Global stocks falter as Gilead halts trial of potential coronavirus treatment
Related news
- FGilead criticised over ‘orphan status’ for potential virus treatmentft.com
- BFDA Rejects Potential Gilead Blockbusters, Scrambling Drug Stocksbarrons.com
- Stocks Cut Gains, Despite Oil Rebound, After Gilead Trial DisappointsForbes
- BGilead, Moderna Stocks Surge. Is It Coronavirus Hype?barrons.com
- US stock futures and Asian markets jump following Gilead drug trial report, Boeing plans to resume productionCNN
- Experimental coronavirus treatment remdesivir delivers 'positive data' in trial, says developer GileadFox News
- EU drugs agency evaluates potential coronavirus treatmentPolitico.eu
- MGilead prices remdesivir at $2,340 for treatment in most of the developed worldmarketwatch.com
- Coronavirus: Bay Area-based Gilead earns FDA approval for COVID-19 treatmentSan Jose Mercury News
- BThe Dow Is Soaring After Gilead Says Coronavirus Treatment Met Trial Goalbarrons.com
- Asia stocks slip, euro down as Greek debt talks falterTimesDaily.com
- European Stocks Falter after Macron's Victory Confirmedthenews.mx
- Dow up 198: Stocks falter on Fed rate signal, recoverUSA today
- Report: AstraZeneca Contacted Gilead For Potential MergerForbes
- Euro stocks falter after Macron win confirmedThe Salt Lake Tribune
- Asian stocks suffer after Trump says trade deal might have to waitCNN
- Asia tech stocks fall after Trump renews US-China trade warCNN